Retatrutide's phase 2 weight curve was still falling when the study ended

In a phase 2 trial, retatrutide took the highest-dose group down roughly a quarter of body weight by 48 weeks against about two percent on placebo, and the curve had not flattened at the last measurement. In that arm 100%, 93% and 83% of participants cleared the 5, 10 and 15 percent marks, and one in four lost 30% of what they started at.

Three receptors explain the size of it. Retatrutide is an investigational weekly injection built to engage GLP-1, GIP and glucagon at once, so appetite is only one lever and the third one lifts resting energy use. A companion phase 2 study in type 2 diabetes randomized 281 people and left 80% of the top-dose group under 7% glycated hemoglobin.

Glucose is where the ceiling shows. The fall in glycated hemoglobin came in close to 2%, a level other existing therapies already reach, so that endpoint looks like it is flattening even while the weight number keeps moving. Both readouts are phase 2, presented at a diabetes congress in 2023, and the physician who reviewed them declares a speaker relationship with a laboratory.

What comes next is phase 3, which these results point toward. Whether any of it belongs in a person's care is a question for a qualified clinician who knows their health history, and retatrutide is still investigational.

Read the full story at Medscape en Español ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.